Official and regulatory announcements from Abera Bioscience, including financial reports, clinical trial updates, and material corporate events.
Abera and partners from The Netherlands, Germany, Switzerland, Denmark and Italy receive more than 2.5 MEUR of funding from the EU for the project Novel vaccine vectors resist pathogen challenge – VacPath. VacPath is a Horizon 2020 MSCA-funded Innovative Training Network that aims to develop novel vector-based vaccines eliciting mucosal
Abera and Denmark-based collaborators Expres2ion Biotechnologies ApS and University of Copenhagen have received Eurostars funding for the project named OptiFemVac. Aim of the project is to develop vaccines targeting female reproductive and infant health, enhanced by delivery platforms designed to produce and deliver efficacious vaccines more cost effectively. The platforms